These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

319 related articles for article (PubMed ID: 28461207)

  • 1. Efficacy and safety of ridinilazole compared with vancomycin for the treatment of Clostridium difficile infection: a phase 2, randomised, double-blind, active-controlled, non-inferiority study.
    Vickers RJ; Tillotson GS; Nathan R; Hazan S; Pullman J; Lucasti C; Deck K; Yacyshyn B; Maliakkal B; Pesant Y; Tejura B; Roblin D; Gerding DN; Wilcox MH;
    Lancet Infect Dis; 2017 Jul; 17(7):735-744. PubMed ID: 28461207
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cadazolid for the treatment of Clostridium difficile infection: results of two double-blind, placebo-controlled, non-inferiority, randomised phase 3 trials.
    Gerding DN; Cornely OA; Grill S; Kracker H; Marrast AC; Nord CE; Talbot GH; Buitrago M; Gheorghe Diaconescu I; Murta de Oliveira C; Preotescu L; Pullman J; Louie TJ; Wilcox MH
    Lancet Infect Dis; 2019 Mar; 19(3):265-274. PubMed ID: 30709665
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Randomized, Double-Blind, Phase 3 Safety and Efficacy Study of Ridinilazole Versus Vancomycin for Treatment of Clostridioides difficile Infection: Clinical Outcomes With Microbiome and Metabolome Correlates of Response.
    Okhuysen PC; Ramesh MS; Louie T; Kiknadze N; Torre-Cisneros J; de Oliveira CM; Van Steenkiste C; Stychneuskaya A; Garey KW; Garcia-Diaz J; Li J; Duperchy E; Chang BY; Sukbuntherng J; Montoya JG; Styles L; Clow F; James D; Dubberke ER; Wilcox M
    Clin Infect Dis; 2024 Jun; 78(6):1462-1472. PubMed ID: 38305378
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fidaxomicin versus vancomycin for infection with Clostridium difficile in Europe, Canada, and the USA: a double-blind, non-inferiority, randomised controlled trial.
    Cornely OA; Crook DW; Esposito R; Poirier A; Somero MS; Weiss K; Sears P; Gorbach S;
    Lancet Infect Dis; 2012 Apr; 12(4):281-9. PubMed ID: 22321770
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antimicrobial susceptibility and ribotypes of Clostridium difficile isolates from a Phase 2 clinical trial of ridinilazole (SMT19969) and vancomycin.
    Snydman DR; McDermott LA; Thorpe CM; Chang J; Wick J; Walk ST; Vickers RJ
    J Antimicrob Chemother; 2018 Aug; 73(8):2078-2084. PubMed ID: 29718329
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of fidaxomicin for the treatment of Clostridioides (Clostridium) difficile infection in a randomized, double-blind, comparative Phase III study in Japan.
    Mikamo H; Tateda K; Yanagihara K; Kusachi S; Takesue Y; Miki T; Oizumi Y; Gamo K; Hashimoto A; Toyoshima J; Kato K
    J Infect Chemother; 2018 Sep; 24(9):744-752. PubMed ID: 29934056
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fidaxomicin versus vancomycin for Clostridium difficile infection.
    Louie TJ; Miller MA; Mullane KM; Weiss K; Lentnek A; Golan Y; Gorbach S; Sears P; Shue YK;
    N Engl J Med; 2011 Feb; 364(5):422-31. PubMed ID: 21288078
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Enhanced preservation of the human intestinal microbiota by ridinilazole, a novel Clostridium difficile-targeting antibacterial, compared to vancomycin.
    Thorpe CM; Kane AV; Chang J; Tai A; Vickers RJ; Snydman DR
    PLoS One; 2018; 13(8):e0199810. PubMed ID: 30071046
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ridinilazole: a novel, narrow-spectrum antimicrobial agent targeting Clostridium (Clostridioides) difficile.
    Collins DA; Riley TV
    Lett Appl Microbiol; 2022 Sep; 75(3):526-536. PubMed ID: 35119124
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ridinilazole: a novel therapy for Clostridium difficile infection.
    Vickers RJ; Tillotson G; Goldstein EJ; Citron DM; Garey KW; Wilcox MH
    Int J Antimicrob Agents; 2016 Aug; 48(2):137-43. PubMed ID: 27283730
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety, immunogenicity, and efficacy of a Clostridioides difficile toxoid vaccine candidate: a phase 3 multicentre, observer-blind, randomised, controlled trial.
    de Bruyn G; Gordon DL; Steiner T; Tambyah P; Cosgrove C; Martens M; Bassily E; Chan ES; Patel D; Chen J; Torre-Cisneros J; Fernando De Magalhães Francesconi C; Gesser R; Jeanfreau R; Launay O; Laot T; Morfin-Otero R; Oviedo-Orta E; Park YS; Piazza FM; Rehm C; Rivas E; Self S; Gurunathan S
    Lancet Infect Dis; 2021 Feb; 21(2):252-262. PubMed ID: 32946836
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Surotomycin versus vancomycin for Clostridium difficile infection: Phase 2, randomized, controlled, double-blind, non-inferiority, multicentre trial.
    Lee CH; Patino H; Stevens C; Rege S; Chesnel L; Louie T; Mullane KM
    J Antimicrob Chemother; 2016 Oct; 71(10):2964-71. PubMed ID: 27432604
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of first recurrence of Clostridium difficile infection: fidaxomicin versus vancomycin.
    Cornely OA; Miller MA; Louie TJ; Crook DW; Gorbach SL
    Clin Infect Dis; 2012 Aug; 55 Suppl 2(Suppl 2):S154-61. PubMed ID: 22752865
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Randomized Controlled Trial of Oral Vancomycin Treatment in Clostridioides difficile-Colonized Patients.
    Fishbein SRS; Hink T; Reske KA; Cass C; Struttmann E; Iqbal ZH; Seiler S; Kwon JH; Burnham CA; Dantas G; Dubberke ER
    mSphere; 2021 Jan; 6(1):. PubMed ID: 33441409
    [No Abstract]   [Full Text] [Related]  

  • 15. Ridinilazole for the treatment of Clostridioides difficile infection.
    Carlson TJ; Endres BT; Bassères E; Gonzales-Luna AJ; Garey KW
    Expert Opin Investig Drugs; 2019 Apr; 28(4):303-310. PubMed ID: 30767587
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Faecal microbiota transplantation for first or second Clostridioides difficile infection (EarlyFMT): a randomised, double-blind, placebo-controlled trial.
    Baunwall SMD; Andreasen SE; Hansen MM; Kelsen J; Høyer KL; Rågård N; Eriksen LL; Støy S; Rubak T; Damsgaard EMS; Mikkelsen S; Erikstrup C; Dahlerup JF; Hvas CL
    Lancet Gastroenterol Hepatol; 2022 Dec; 7(12):1083-1091. PubMed ID: 36152636
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Multicenter, Double-Blind, Randomized, Phase 2 Study Evaluating the Novel Antibiotic Cadazolid in Patients with Clostridium difficile Infection.
    Louie T; Nord CE; Talbot GH; Wilcox M; Gerding DN; Buitrago M; Kracker H; Charef P; Cornely OA
    Antimicrob Agents Chemother; 2015 Oct; 59(10):6266-73. PubMed ID: 26248357
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Multicenter, randomized clinical trial to compare the safety and efficacy of LFF571 and vancomycin for Clostridium difficile infections.
    Mullane K; Lee C; Bressler A; Buitrago M; Weiss K; Dabovic K; Praestgaard J; Leeds JA; Blais J; Pertel P
    Antimicrob Agents Chemother; 2015 Mar; 59(3):1435-40. PubMed ID: 25534727
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Extended-pulsed fidaxomicin versus vancomycin for Clostridium difficile infection in patients 60 years and older (EXTEND): a randomised, controlled, open-label, phase 3b/4 trial.
    Guery B; Menichetti F; Anttila VJ; Adomakoh N; Aguado JM; Bisnauthsing K; Georgopali A; Goldenberg SD; Karas A; Kazeem G; Longshaw C; Palacios-Fabrega JA; Cornely OA; Vehreschild MJGT;
    Lancet Infect Dis; 2018 Mar; 18(3):296-307. PubMed ID: 29273269
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and Safety of RBX2660 in PUNCH CD3, a Phase III, Randomized, Double-Blind, Placebo-Controlled Trial with a Bayesian Primary Analysis for the Prevention of Recurrent Clostridioides difficile Infection.
    Khanna S; Assi M; Lee C; Yoho D; Louie T; Knapple W; Aguilar H; Garcia-Diaz J; Wang GP; Berry SM; Marion J; Su X; Braun T; Bancke L; Feuerstadt P
    Drugs; 2022 Oct; 82(15):1527-1538. PubMed ID: 36287379
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.